Generative AI for Drug Discovery
Designing Novel Modalities, Optimizing Drug Candidates, Closing the DMTA Loop
April 19, 2027 ALL TIMES PDT
Generative AI (GenAI) models and algorithms show promise in designing and optimizing lead candidates with desirable drug-like properties and for exploring complex biology and expansive chemical space. However, do we fully understand their scope, impact, and nuances for early drug discovery applications? Cambridge Healthtech Institute’s symposium on Generative AI for Drug Discovery will bring together key stakeholders from pharma/biotech companies, technology providers, and academia to discuss what is currently being done and what is possible in the near future. These discussions on applications of GenAI are a good primer for the AI/ML for Early Drug Discovery conferences that follow.
Preliminary Agenda

IMPACT OF GENERATIVE AI

Chairperson's Remarks

Tudor Oprea, MD, PhD, Chief AIDD Officer, Dompé , Chief AIDD Officer , Dompé

A Drug Hunter's Guide to the AI/ML Galaxy

Photo of Tudor Oprea, MD, PhD, Chief AIDD Officer, Dompé , Chief AIDD Officer , Dompé
Tudor Oprea, MD, PhD, Chief AIDD Officer, Dompé , Chief AIDD Officer , Dompé

Closing the "Make" Gap: Generative Design plus Make-on-Demand Chemistry for a Novel PRMT6 Allosteric Site

Photo of Brian Atwood, PhD, Scientific Program Lead, Drug Discovery, Variational AI , Scientific Program Lead , Drug Discovery , Variational AI
Brian Atwood, PhD, Scientific Program Lead, Drug Discovery, Variational AI , Scientific Program Lead , Drug Discovery , Variational AI

Generative AI designs that cannot be synthesized are worthless. By generatively modeling synthesizability alongside potency and ADMET, in a single model, we are able to design molecules in any region of chemical space, including make-on-demand space. In collaboration with the Agora Open Science Trust and Enamine, we've generated candidates against a novel allosteric site on PRMT6, constrained to synthetically accessible chemistry, then docked and prioritized them for make-on-demand synthesis.

AI-Guided Therapeutic Design for Antigen Escape Prediction, Molecular Optimization, and Construct Engineering

Photo of Alireza Daneshvar, Co-Founder & CEO, Pioneera Biosciences , Co-Founder & CEO , Pioneera Biosciences
Alireza Daneshvar, Co-Founder & CEO, Pioneera Biosciences , Co-Founder & CEO , Pioneera Biosciences

From Model Validation to Clinical Translation: Closing the Gap in AI-Driven Drug Discovery

Photo of Petrina Kamya, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada , Global Head of AI Platforms, VP , Insilico Medicine, Canada
Petrina Kamya, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada , Global Head of AI Platforms, VP , Insilico Medicine, Canada

BRAINSTORMING SESSION

Discussion on True Impact of Generative AI on Yielding Early Clinical Assets

For more details on the conference, please contact:
Tanuja Koppal, PhD
Senior Conference Director
Cambridge Healthtech Institute
Email: tkoppal@healthtech.com

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: kskahan@healthtech.com

#DrugDiscoveryChemistry
Register Early for Maximum Savings
View Preliminary Agenda
Join The Mailing List
Sponsor And Exhibit
View the 2026 Photo Gallery

APRIL 19

Covalent & Induced Proximity-Based Therapies

RNA-Modulating Small Molecule Drugs

Generative AI for Drug Discovery

training seminars

View In-Person Short Courses

APRIL 20 - 21

Degraders & Molecular Glues - Part 1

Small Molecule Discovery Technologies

AI/ML for Early Drug Discovery - Part 1

Linker & Conjugation Chemistries

Peptides

APRIL 21 - 22

Degraders & Molecular Glues - Part 2

Protein-Protein Interactions / Difficult Targets

AI/ML for Early Drug Discovery - Part 2

DNA-Encoded Libraries

GLP1 & Oral Peptides

Drug Discovery Chemsitry Europe

View All Sponsors

View All Media Partners